Teva Pharmaceutical Industries ADR
(TEVA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,597,000 | 3,042,000 | 1,253,000 | 1,910,000 | 2,768,000 |
| Depreciation Amortization | 1,308,000 | 1,508,000 | 1,642,000 | 1,708,000 | 1,069,000 |
| Income taxes - deferred | 237,000 | -226,000 | -1,380,000 | -690,000 | -500,000 |
| Accounts receivable | 763,000 | 710,000 | N/A | N/A | 701,000 |
| Other Working Capital | 967,000 | 290,000 | 968,000 | 414,000 | 594,000 |
| Other Operating Activity | 670,000 | -197,000 | 754,000 | 1,230,000 | -498,000 |
| Operating Cash Flow | $5,542,000 | $5,127,000 | $3,237,000 | $4,572,000 | $4,134,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -248,000 | -733,000 | -844,000 | -840,000 | -774,000 |
| Net Acquisitions | -3,309,000 | -363,000 | -39,000 | N/A | -6,561,000 |
| Purchase Of Investment | -2,003,000 | -324,000 | -160,000 | -201,000 | -217,000 |
| Other Investing Activity | -5,000 | -30,000 | -104,000 | -93,000 | -49,000 |
| Investing Cash Flow | $-5,565,000 | $-1,450,000 | $-1,147,000 | $-1,134,000 | $-7,601,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 29,000 | -385,000 | 384,000 | -2,492,000 | -124,000 |
| Debt Issued | 5,390,000 | N/A | 338,000 | 5,024,000 | 6,723,000 |
| Debt Repayment | -2,521,000 | -839,000 | -3,133,000 | -2,213,000 | -1,565,000 |
| Common Stock Issued | 3,679,000 | 514,000 | 91,000 | 14,000 | 71,000 |
| Common Stock Repurchased | -439,000 | -500,000 | -497,000 | -1,161,000 | -899,000 |
| Dividend Paid | -1,155,000 | -1,156,000 | -1,089,000 | -855,000 | -800,000 |
| Other Financing Activity | -178,000 | -9,000 | 23,000 | 5,000 | -70,000 |
| Financing Cash Flow | $4,805,000 | $-2,375,000 | $-3,883,000 | $-1,678,000 | $3,336,000 |
| Exchange Rate Effect | -62,000 | -114,000 | -48,000 | 23,000 | -21,000 |
| Beginning Cash Position | 2,226,000 | 1,038,000 | 2,879,000 | 1,096,000 | 1,248,000 |
| End Cash Position | 6,946,000 | 2,226,000 | 1,038,000 | 2,879,000 | 1,096,000 |
| Net Cash Flow | $4,720,000 | $1,188,000 | $-1,841,000 | $1,783,000 | $-152,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 5,542,000 | 5,127,000 | 3,237,000 | 4,572,000 | 4,134,000 |
| Capital Expenditure | -772,000 | -929,000 | -1,031,000 | -1,104,000 | -1,053,000 |
| Free Cash Flow | 4,770,000 | 4,198,000 | 2,206,000 | 3,468,000 | 3,081,000 |